Paibel I. Aguayo-Hiraldo

Hematology | Oncology

550 S Beretania St Ste 201
Honolulu, HI 96813

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

Journal: medRxiv : the preprint server for health sciences

Published: July 29, 2026

High Predicted Thiotepa Exposure is Associated with Increased Risk of Thrombotic Microangiopathy and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation.

High Predicted Thiotepa Exposure is Associated with Increased Risk of Thrombotic Microangiopathy and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation.

Journal: Transplantation and cellular therapy

Published: June 09, 2026

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Journal: Blood immunology & cellular therapy

Published: May 15, 2026

Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study.

Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study.

Journal: Transplantation and cellular therapy

Published: December 11, 2025

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Journal: Transplantation and cellular therapy

Published: July 31, 2025

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

Journal: Blood advances

Published: May 09, 2025

Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.

Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.

Journal: Blood advances

Published: April 14, 2025

Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy.

Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy.

Journal: Leukemia & lymphoma

Published: March 25, 2025

High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation.

High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation.

Journal: Transplantation and cellular therapy

Published: January 22, 2025

A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemia.

A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemia.

Journal: Frontiers in oncology

Published: December 07, 2024

Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: September 25, 2024

Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT.

Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT.

Journal: Bone marrow transplantation

Published: September 18, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026